PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Thumbnail

Researcher in hot water after manipulating PET imaging data for grant application

The researcher was seeking funding to further her study on the development of psychosis based on findings visualized on PET imaging.

Brain scans reveal single doses of nicotine inhibiting estrogen production in women

On MRI and PET brain scans, women who were exposed to a small dose of nicotine showed altered activity in the thalamus region of the brain.

Thumbnail

CRC patients with these clinical characteristics need more frequent post-op chest imaging

These patients are at greatest risk of developing lung metastases within three months of surgery.

Thumbnail

PET/CT findings predict post-treatment, radiation-induced hypothyroidism

Radiation-induced hypothyroidism is common yet underdiagnosed, potentially owing to a lack of follow-up consensus in patients treated with radiation therapy for head and neck cancers.

Thumbnail

FAPI PET/CT findings linked with risk of sudden cardiac death

Experts involved in the research suggested that these findings indicate a potential role for FAPI PET/CT imaging in detecting changes in myocardial fibrosis, noting that it could be more sensitive to earlier changes than standard cardiac MRI.

cerebral palsy PET imaging

How PET imaging could benefit children with cerebral palsy

These new findings could help providers differentiate and manage CP associated with different levels of motor impairment, authors of the study indicated.

Thumbnail

New lesion measurement assesses treatment responses more accurately than RECIST

Researchers believe the new method of assessing treatment responses could pave the way for developing new cancer therapeutics.

Thumbnail

A new Alzheimer's drug therapy appears effective. What might this mean for the future of amyloid PET?

Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.